LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Mirati Therapeutics Inc

Search

Mirati Therapeutics Inc

Fermé

Secteur Soins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés
By Trading Economics
Revenu	-162M
Ventes	16M
BPA	-2.49
Marge bénéficiaire	-987.22
EBITDA	-171M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	-0.05 downside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-41M 4.1B
Ouverture précédente	0
Clôture précédente	0

Sentiment de l'Actualité

By Acuity

11%

89%

9 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

58.54 / 58.9 Support & Résistance

Mirati Therapeutics Inc Graphique

Actualités Associées

9 oct. 2023, 14:15 UTC

Acquisitions, Fusions, Rachats

Trending: Bristol Myers Squibb Buying Mirati Therapeutics

9 oct. 2023, 10:11 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Mirati Shares Slip Premarket on Bristol Myers Takeover

6 oct. 2023, 06:41 UTC

Acquisitions, Fusions, Rachats

Sanofi Considering Acquisition of Mirati Therapeutics, Bloomberg Reports

23 janv. 2024, 13:30 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics

9 oct. 2023, 15:25 UTC

Acquisitions, Fusions, Rachats

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid -- IBD

9 oct. 2023, 13:56 UTC

Market Talk

Acquisitions, Fusions, Rachats

Bristol Still Has Flexibility After Mirati Deal -- Market Talk

9 oct. 2023, 13:52 UTC

Acquisitions, Fusions, Rachats

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid -- IBD

9 oct. 2023, 13:40 UTC

Market Talk

Acquisitions, Fusions, Rachats

Guggenheim: Bristol-Mirati Deal Plugs Bristol's Holes -- Market Talk

9 oct. 2023, 11:18 UTC

Market Talk

Acquisitions, Fusions, Rachats

Bristol Hedges Mirati Bet With MRTX1719 CVRs -- Market Talk

9 oct. 2023, 09:27 UTC

Acquisitions, Fusions, Rachats

Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion -- Barrons.com

8 oct. 2023, 22:12 UTC

Actualités

Acquisitions, Fusions, Rachats

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion -- WSJ

8 oct. 2023, 21:34 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb to Finance Transaction With Cash and Debt

8 oct. 2023, 21:34 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb: Transaction Will Be EPS Dilutive by $0.12/Share in First 12 Months

8 oct. 2023, 21:29 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb: Non-Tradeable Rights Add $1 Bln of Value Opportunity

8 oct. 2023, 21:29 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb: Mirati Board Unanimously Approves Transaction

8 oct. 2023, 21:28 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb Will Also Pay One Contingent Value Right Per Share

8 oct. 2023, 21:27 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb: Acquisition Values Mirati's Equity at $4.8 Bln

8 oct. 2023, 21:26 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb to Acquire Mirati for $58/Share in Cash

8 oct. 2023, 21:26 UTC

Acquisitions, Fusions, Rachats

Bristol-Myers Squibb: Transaction to Be Dilutive to Co's Non-GAAP EPS by About 35c/Shr in First 12 Mos After Transaction Closes >BMY

8 oct. 2023, 21:25 UTC

Acquisitions, Fusions, Rachats

Bristol-Myers Squibb To Acquire Mirati for $58 Per Shr in Cash, for a Total Equity Value of $4.8B >BMY MRTX

Comparaison

Variation de prix

Mirati Therapeutics Inc prévision

Objectif de Prix

By TipRanks

-0.05% baisse

Prévisions sur 12 Mois

Moyen 58.67 USD -0.05%

Haut 59 USD

Bas 58 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

0

Achat

5

Maintien

0

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

58.54 / 58.9Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

9 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.

Autres valeurs du secteur

LLY

Eli Lilly and Co.

902.74

UNH

UnitedHealth Group Inc

596.8

NVO

Novo Nordisk A-S

131.05

JNJ

Johnson and Johnson

164.37

ABBV

AbbVie Inc

193.18